CAPR Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2024-04-01 | 2023 | Karen Krasney, J.D. Executive Vice President & General Counsel | 362,250 | 52,400 | 0 | 0 | 12,072 | 740,769 |
| 2024-04-01 | 2022 | Linda Marbán, Ph.D. Chief Executive Officer | 210,000 | 63,000 | 0 | 0 | 9,300 | 1,333,423 |
| 2024-04-01 | 2023 | Linda Marbán, Ph.D. Chief Executive Officer | 220,500 | 50,115 | 0 | 0 | 10,005 | 747,315 |
| 2024-04-01 | 2022 | Anthony Bergmann, M.B.A. Chief Financial Officer | 345,000 | 103,500 | 0 | 0 | 10,650 | 923,688 |
| 2024-04-01 | 2023 | Anthony Bergmann, M.B.A. Chief Financial Officer | 362,250 | 63,350 | 0 | 0 | 11,400 | 730,845 |
| 2024-04-01 | 2022 | Karen Krasney, J.D. Executive Vice President & General Counsel | 345,000 | 78,500 | 0 | 0 | 11,032 | 668,443 |
| 2023-04-17 | 2022 | Anthony Bergmann, M.B.A. Chief Financial Officer | 345,000 | 103,500 | 0 | 0 | 10,650 | 923,688 |
| 2023-04-17 | 2022 | Linda Marbán, Ph.D. Chief Executive Officer | 210,000 | 63,000 | 0 | 0 | 9,300 | 1,333,423 |
| 2023-04-17 | 2021 | Linda Marbán, Ph.D. Chief Executive Officer | 200,000 | 68,745 | 0 | 0 | 25,088 | 1,790,548 |
| 2023-04-17 | 2022 | Karen Krasney, J.D. Executive Vice President & General Counsel | 345,000 | 78,500 | 0 | 0 | 11,032 | 668,443 |
| 2023-04-17 | 2021 | Karen Krasney, J.D. Executive Vice President & General Counsel | 330,750 | 33,075 | 0 | 0 | 10,200 | 686,271 |
| 2023-04-17 | 2021 | Anthony Bergmann, M.B.A. Chief Financial Officer | 315,000 | 75,000 | 0 | 0 | 15,723 | 717,969 |
| 2022-04-12 | 2020 | Anthony Bergmann, M.B.A. Chief Financial Officer | 287,500 | 27,500 | 0 | 0 | 1,500 | 792,192 |
| 2022-04-12 | 2020 | Linda Marbán, Ph.D. Chief Executive Officer | 150,000 | 45,000 | 0 | 0 | 1,500 | 1,657,032 |
| 2022-04-12 | 2021 | Karen Krasney, J.D. Executive Vice President & General Counsel | 200,000 | 68,745 | 0 | 0 | 18,526 | 1,783,986 |
| 2022-04-12 | 2020 | Karen Krasney, J.D. Executive Vice President & General Counsel | 313,750 | 31,500 | 0 | 0 | 1,500 | 762,605 |
| 2022-04-12 | 2021 | Anthony Bergmann, M.B.A. Chief Financial Officer | 330,750 | 33,075 | 0 | 0 | 1,500 | 677,571 |
| 2021-04-20 | 2019 | Linda Marbán, Ph.D. Chief Executive Officer | 156,909 | 0 | 0 | 0 | 1,500 | 228,919 |
| 2021-04-20 | 2020 | Karen Krasney, J.D. Executive Vice President & General Counsel | 150,000 | 45,000 | 0 | 0 | 1,500 | 1,657,032 |
| 2021-04-20 | 2019 | Karen Krasney, J.D. Executive Vice President & General Counsel | 300,000 | 0 | 0 | 0 | 1,500 | 340,327 |
| 2021-04-20 | 2020 | Anthony Bergmann Chief Financial Officer | 313,750 | 31,500 | 0 | 0 | 1,500 | 762,605 |
| 2021-04-20 | 2019 | Anthony Bergmann Chief Financial Officer | 212,500 | 0 | 0 | 0 | 1,500 | 252,827 |
| 2020-04-17 | 2018 | Anthony Bergmann Chief Financial Officer | 200,000 | 0 | 0 | 0 | 1,000 | 273,700 |
| 2020-04-17 | 2018 | Linda Marbán, Ph.D. Chief Executive Officer | 232,909 | 0 | 0 | 0 | 0 | 377,471 |
| 2020-04-17 | 2019 | Karen Krasney, J.D. Executive Vice President & General Counsel | 156,909 | 0 | 0 | 0 | 1,500 | 228,919 |
| 2020-04-17 | 2018 | Karen Krasney, J.D. Executive Vice President & General Counsel | 300,000 | 0 | 0 | 0 | 1,000 | 351,890 |
| 2020-04-17 | 2019 | Anthony Bergmann Chief Financial Officer | 300,000 | 0 | 0 | 0 | 1,500 | 340,327 |
| 2019-04-30 | 2018 | Karen Krasney, J.D. Executive Vice President & General Counsel | 232,909 | 0 | 0 | 0 | 0 | 377,471 |
| 2019-04-30 | 2017 | Anthony Bergmann Chief Financial Officer | 154,500 | 0 | 0 | 0 | 1,000 | 220,110 |
| 2019-04-30 | 2018 | Anthony Bergmann Chief Financial Officer | 244,451 | 0 | 0 | 0 | 1,000 | 364,897 |
| 2019-04-30 | 2017 | Deborah Ascheim, M.D. Former Chief Medical Officer | 255,000 | 0 | 0 | 0 | 1,000 | 348,300 |
| 2019-04-30 | 2018 | Deborah Ascheim, M.D. Former Chief Medical Officer | 300,000 | 0 | 0 | 0 | 1,000 | 351,890 |
| 2019-04-30 | 2017 | Karen Krasney, J.D. Executive Vice President & General Counsel | 262,500 | 0 | 0 | 0 | 1,000 | 309,650 |
| 2019-04-30 | 2017 | Linda Marbán, Ph.D. Chief Executive Officer | 232,909 | 0 | 0 | 0 | 0 | 602,109 |
| 2018-04-26 | 2017 | Karen Krasney, J.D. Executive Vice President & General Counsel | 232,909 | 0 | 0 | 0 | 0 | 602,109 |
| 2018-04-26 | 2016 | Deborah Ascheim, M.D. Chief Medical Officer | 250,000 | 0 | 0 | 0 | 1,000 | 250,333 |
| 2018-04-26 | 2017 | Deborah Ascheim, M.D. Chief Medical Officer | 262,500 | 0 | 0 | 0 | 1,000 | 309,650 |
| 2018-04-26 | 2016 | Karen Krasney, J.D. Executive Vice President & General Counsel | 259,375 | 0 | 0 | 0 | 1,000 | 373,875 |
| 2018-04-26 | 2016 | Linda Marbán, Ph.D. Chief Executive Officer | 232,909 | 0 | 0 | 0 | 0 | 232,909 |
| 2017-04-21 | 2016 | Karen Krasney, J.D. Executive Vice President & General Counsel Leland Gershell, M.D., Ph.D. Chief Financial Officer | 232,909 | 0 | 0 | 0 | 0 | 232,909 |
| 2017-04-21 | 2015 | Linda Marbán, Ph.D. Chief Executive Officer | 232,909 | 0 | 0 | 0 | 0 | 1,302,810 |
| 2017-04-21 | 2015 | Karen Krasney, J.D. Executive Vice President & General Counsel Leland Gershell, M.D., Ph.D. Chief Financial Officer | 254,167 | 0 | 0 | 0 | 1,000 | 383,555 |
| 2016-04-28 | 2014 | Karen Krasney, J.D. Executive Vice President & General Counsel | 243,750 | 0 | 0 | 0 | 1,000 | 244,750 |
| 2016-04-28 | 2015 | Karen Krasney, J.D. Executive Vice President & General Counsel | 232,909 | 0 | 0 | 0 | 0 | 1,302,810 |
| 2016-04-28 | 2014 | Linda Marbán, Ph.D. Chief Executive Officer | 232,909 | 0 | 0 | 0 | 0 | 232,909 |
| 2016-04-28 | 2014 | Deborah Ascheim, M.D. Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2016-04-28 | 2015 | Deborah Ascheim, M.D. Chief Medical Officer | 254,167 | 0 | 0 | 0 | 1,000 | 383,555 |
| 2015-05-18 | 2013 | Linda Marbán, Ph.D. Chief Executive Officer | 232,344 | 0 | 0 | 0 | 0 | 340,544 |
| 2015-05-18 | 2013 | Karen Krasney, J.D. Executive Vice President & General Counsel | 189,390 | 0 | 0 | 0 | 1,000 | 190,390 |
| 2015-05-18 | 2013 | Andrew Hamer, M.D. Vice President of Medical Affairs | 28,977 | 0 | 0 | 0 | 0 | 53,738 |
| 2015-05-18 | 2014 | Andrew Hamer, M.D. Vice President of Medical Affairs | 243,750 | 0 | 0 | 0 | 1,000 | 244,750 |
| 2015-05-18 | 2014 | Karen Krasney, J.D. Executive Vice President & General Counsel | 232,909 | 0 | 0 | 0 | 0 | 232,909 |
| 2014-09-17 | 2012 | Anthony Davies, Ph.D. Former Chief Technology Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2014-09-17 | 2012 | Linda Marbán, Ph.D. Chief Executive Officer | 190,313 | 0 | 0 | 0 | 0 | 190,313 |
| 2014-09-17 | 2013 | Karen Krasney, J.D. Executive Vice President & General Counsel | 232,344 | 0 | 0 | 0 | 0 | 340,344 |
| 2014-09-17 | 2012 | Karen Krasney, J.D. Executive Vice President & General Counsel | 130,000 | 0 | 0 | 0 | 1,000 | 185,747 |
| 2014-09-17 | 2013 | Anthony Davies, Ph.D. Former Chief Technology Officer | 189,390 | 0 | 0 | 0 | 1,000 | 190,390 |
| 2014-09-17 | 2013 | Darlene Horton, M.D. Former Chief Executive Officer | 213,083 | 0 | 0 | 0 | 40,554 | 302,909 |
| 2014-09-17 | 2012 | Darlene Horton, M.D. Former Chief Executive Officer | 81,439 | 0 | 0 | 0 | 0 | 81,439 |
| 2013-10-10 | 2012 | Richard B. Brewer Former Executive Chairman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2013-10-10 | 2012 | Darlene Horton, M.D. President & CEO | 81,439 | 0 | 0 | 0 | 0 | 81,439 |
| 2013-10-10 | 2011 | Richard B. Brewer Former Executive Chairman | 240,000 | 0 | 0 | 0 | 0 | 322,626 |
| 2013-10-10 | 2012 | Joshua A. Kazam Former President & CEO | 0 | 0 | 0 | 0 | 0 | 0 |
| 2013-10-10 | 2011 | Joshua A. Kazam Former President & CEO | 0 | 0 | 0 | 0 | 0 | 35,321 |
| 2013-10-10 | 2012 | Daron Evans Chief Financial Officer | 275,000 | 0 | 0 | 0 | 30,805 | 305,805 |
| 2013-10-10 | 2011 | Daron Evans Chief Financial Officer | 252,083 | 87,500 | 0 | 0 | 530 | 361,006 |
| 2011-04-08 | 2010 | Joshua A. Kazam President & CEO | 0 | 0 | 0 | 0 | 0 | 16,876 |
| 2011-04-08 | 2009 | Joshua A. Kazam President & CEO | 0 | 0 | 0 | 0 | 0 | 80,963 |
| 2011-04-08 | 2010 | Richard B. Brewer Executive Chairman | 107,384 | 0 | 0 | 0 | 0 | 379,283 |
| 2011-04-08 | 2009 | Richard B. Brewer Executive Chairman | 0 | 0 | 0 | 0 | 0 | 0 |
| 2011-04-08 | 2009 | Daron Evans Chief Financial Officer | 200,000 | 20,000 | 0 | 0 | 530 | 300,564 |
| 2011-04-08 | 2010 | Daron Evans Chief Financial Officer | 226,522 | 75,000 | 0 | 0 | 530 | 391,222 |
| 2010-06-15 | 2008 | Daron Evans Chief Financial Officer | 175,000 | 0 | 0 | 0 | 530 | 175,530 |
| 2010-06-15 | 2009 | Joshua Kazam CEO, Director | 0 | 0 | 0 | 0 | 0 | 80,963 |
| 2010-06-15 | 2009 | Peter M. Strumph Former CEO, Director | 143,559 | 0 | 0 | 0 | 250,404 | 448,737 |
| 2010-06-15 | 2008 | Peter M. Strumph Former CEO, Director | 316,329 | 0 | 0 | 0 | 1,210 | 317,539 |
| 2010-06-15 | 2009 | Daron Evans Chief Financial Officer | 200,000 | 20,000 | 0 | 0 | 530 | 300,564 |
| 2010-06-15 | 2009 | Hsiao Lieu VP, Clinical Development | 187,504 | 30,750 | 0 | 0 | 0 | 348,648 |
| 2010-06-15 | 2008 | Hsiao Lieu VP, Clinical Development | 202,724 | 55,685 | 0 | 0 | 0 | 1,269,709 |
| 2009-11-02 | 2008 | Peter M. Strumph Former CEO, Director | 316,329 | 0 | 0 | 0 | 1,210 | 1,390,050 |
| 2009-11-02 | 2007 | Hsiao Lieu VP, Clinical Development | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-11-02 | 2008 | Hsiao Lieu VP, Clinical Development | 202,724 | 55,685 | 0 | 0 | 0 | 485,421 |
| 2009-11-02 | 2007 | Daron Evans Chief Financial Officer | 154,876 | 55,380 | 0 | 0 | 103,198 | 583,734 |
| 2009-11-02 | 2008 | Daron Evans Chief Financial Officer | 175,000 | 0 | 0 | 0 | 530 | 517,080 |
| 2009-11-02 | 2007 | Peter M. Strumph Former CEO, Director | 179,840 | 70,378 | 0 | 0 | 3,535 | 881,740 |
| 2008-04-18 | 2007 | Jennifer Hodge Vice President, Development | 57,974 | 15,181 | 0 | 0 | 425 | 109,422 |
| 2008-04-18 | 2007 | Peter M. Strumph Chief Executive Officer, Director | 179,840 | 70,378 | 0 | 0 | 3,535 | 881,740 |
| 2008-04-18 | 2007 | Daron Evans Chief Financial Officer | 154,876 | 55,380 | 0 | 0 | 103,198 | 583,734 |
| 2008-04-18 | 2007 | Allan Gordon Former Chief Executive Officer | 116,129 | 100,000 | 0 | 0 | 489,404 | 1,667,208 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
